eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg…